Scholarlink

Background <p>Regarding concurrent chemoradiotherapy (CCRT), the combination of docetaxel and cisplatin (DP regimen) is a promising option for treating head and neck squamous cell carcinoma (HNSCC) with a relatively low dose of cisplatin; however, its non-inferiority to other chemotherapies in efficacy and tolerability remains unclear.</p> Methods <p>In this retrospective multi-institutional study, the efficacy and safety of the DP regimen were compared with those of other chemotherapy regimens in patients who underwent CCRT for HNSCC. Overall survival, progression-free survival, and adverse effects—including estimated glomerular filtration rate (eGFR)—were evaluated as outcome measures.</p> Results <p>Study results showed that a total of 211 patients were included. The prevalence of oropharyngeal, hypopharyngeal, and laryngeal cancer was 44%, 33%, and 17%, respectively. Overall response and recurrence rates were comparable between the DP regimen and high-dose CDDP alone. Although overall and progression-free survival tended to be longer with the DP regimen than with high-dose CDDP, the differences were not statistically significant. Neutropenia was more frequently observed with the DP regimen, but the chemotherapy completion rate was comparable to that of high-dose CDDP alone. Regarding renal function, eGFR significantly decreased with high-dose CDDP but not with the DP regimen.</p> Conclusions <p>A combination of docetaxel and cisplatin in concurrent chemoradiotherapy was a favorable option for treating HNSCC with acceptable efficacy and manageable toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy and safety of docetaxel with cisplatin compared with other chemotherapies in definitive chemoradiotherapy for head and neck squamous cell carcinoma: a real-world study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月20日

查看全文
  • Takumi Kumai,
  • Yuto Izumiya,
  • Misaki Hayashi,
  • Kaoru Miyakoshi,
  • Takahiro Inoue,
  • Hisataka Ominato,
  • Motozumi Nakamura,
  • Risa Wakisaka,
  • Daisuke Araki,
  • Michihisa Kono,
  • Hidekiyo Yamaki,
  • Kenzo Ohara,
  • Yoshiya Ishida,
  • Tomoki Yoshizaki,
  • Tetsuji Wada,
  • Nobuyuki Bandoh,
  • Miki Takahara

摘要

Background

Regarding concurrent chemoradiotherapy (CCRT), the combination of docetaxel and cisplatin (DP regimen) is a promising option for treating head and neck squamous cell carcinoma (HNSCC) with a relatively low dose of cisplatin; however, its non-inferiority to other chemotherapies in efficacy and tolerability remains unclear.

Methods

In this retrospective multi-institutional study, the efficacy and safety of the DP regimen were compared with those of other chemotherapy regimens in patients who underwent CCRT for HNSCC. Overall survival, progression-free survival, and adverse effects—including estimated glomerular filtration rate (eGFR)—were evaluated as outcome measures.

Results

Study results showed that a total of 211 patients were included. The prevalence of oropharyngeal, hypopharyngeal, and laryngeal cancer was 44%, 33%, and 17%, respectively. Overall response and recurrence rates were comparable between the DP regimen and high-dose CDDP alone. Although overall and progression-free survival tended to be longer with the DP regimen than with high-dose CDDP, the differences were not statistically significant. Neutropenia was more frequently observed with the DP regimen, but the chemotherapy completion rate was comparable to that of high-dose CDDP alone. Regarding renal function, eGFR significantly decreased with high-dose CDDP but not with the DP regimen.

Conclusions

A combination of docetaxel and cisplatin in concurrent chemoradiotherapy was a favorable option for treating HNSCC with acceptable efficacy and manageable toxicity.